Please login to the form below

Not currently logged in
Email:
Password:

Imfinzi

This page shows the latest Imfinzi news and features for those working in and with pharma, biotech and healthcare.

Is AstraZeneca looking for its next CEO?

Is AstraZeneca looking for its next CEO?

Moreover, AZ has enjoyed a strong 2018, with growth from new oncology products such as Imfinzi, Tagrisso and Lynparza leading it towards a return to growth. ... This includes strong growth in China, key approvals for Imfinzi in stage III lung cancer and

Latest news

  • AZ’s MYSTIC survival data is in – and it’s a bust AZ’s MYSTIC survival data is in – and it’s a bust

    Imfinzi failed to achieve OS improvement. AstraZeneca has released the overall survival (OS) data from its MYSTIC trial of Imfinzi and tremelimumab in advanced non-small cell lung cancer (NSCLC), and ... for tremelimumab look very shaky after the

  • AZ says target of $45bn sales by 2023 still achievable AZ says target of $45bn sales by 2023 still achievable

    The underlying picture is strong, however, with new medicines like Tagrisso, Imfinzi, Lynparza in cancer, Farxiga in diabetes and Fasenra in severe asthma growing 19% in the first nine months of ... Lynparza (olaparib) for ovarian and breast cancer more

  • AZ swells immuno-oncology pipeline with Innate deal AZ swells immuno-oncology pipeline with Innate deal

    AZ has started to make some headway with Imfinzi but its sales are dwarfed by earlier checkpoint inhibitors such as MSD’s Keytruda (pembrolizumab) and BMS’ Opdivo (nivolumab). ... two primary endpoints in the MYSTIC trial of Imfinzi plus AZ’s

  • Imfinzi aces survival challenge in lung cancer Imfinzi aces survival challenge in lung cancer

    Imfinzi to blockbuster status, according to analysts at Moody’s, who say AZ’s rivals are 18 months to two years behind in development. ... Imfinzi plus experimental CTLA4 inhibitor tremelimumab failed to show improved PFS compared to chemotherapy.

  • AstraZeneca chief on Brexit: “It’s going to be really painful” AstraZeneca chief on Brexit: “It’s going to be really painful”

    Now, with new products like cancer drugs Lynparza, Tagrisso and Imfinzi starting to build momentum – plus a fast-growing business in China – Soriot says the company is on a substantially firmer

More from news
Approximately 10 fully matching, plus 34 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 1 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
VCCP Health

We’re the challenger agency for challenger brands. Brands with a point to prove. Rx, OTC and wellness brands run by...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics